Pfizer Inc. announced positive topline results from the Phase III TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an… read more.
Prescriptions for the anti-parasite medication ivermectin doubled in the months following an endorsement by a celebrity during a high-profile podcast as an off-label cancer treatment, a UCLA-led study… read more.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Mekinist. The marketing… read more.
The digital transformation of pathology is opening up new possibilities for cancer diagnosis. Today’s artificial intelligence (AI) techniques now go far beyond mere automation: they make it possible… read more.
EAHP Congress Highlights The timing of immunotherapy administration influences treatment effectiveness, with morning treatment associated with significantly better survival outcomes, according to new real-world data presented at the… read more.
EAHP Congress Highlights Continuous piperacillin/tazobactam infusion via elastomeric pump offers a safe, cost-effective alternative to inpatient antibiotic therapy in paediatric oncology, with measurable benefits for ward capacity, healthcare… read more.
A new scoping review from the University of Toronto reveals that caregivers of loved ones with ovarian cancer face significant emotional strain, heavy caregiving responsibilities, and limited support… read more.
The EMA’s CHMP adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Adstiladrin. Since Adstiladrin is an advanced therapy medicinal product, the… read more.
A cancer diagnosis can upend any life. For young adults already navigating a step into independence, it can be especially distressing. But there are few evidence-based interventions to… read more.
Colorectal cancer (CRC) is the second most common cause of cancer death in the United States and disproportionally impacts people who receive care in under-resourced settings. Fortunately, several… read more.
NICE(UK): Venetoclax plus obinutuzumab can be used, within its marketing authorisation, as an option for untreated chronic lymphocytic leukaemia (CLL) in adults. It can only be used if… read more.
People who have experienced childhood sexual abuse have twice the odds of receiving a cancer diagnosis at age 65 or older compared to others who have not experienced… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
